262 related articles for article (PubMed ID: 37459922)
21. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
23. Bifidobacterium pseudolongum reduces triglycerides by modulating gut microbiota in mice fed high-fat food.
Bo TB; Wen J; Zhao YC; Tian SJ; Zhang XY; Wang DH
J Steroid Biochem Mol Biol; 2020 Apr; 198():105602. PubMed ID: 31987886
[TBL] [Abstract][Full Text] [Related]
24. Intestinal microbiomics and hepatic metabolomics insights into the potential mechanisms of probiotic Bifidobacterium pseudolongum CCFM1253 preventing acute liver injury in mice.
Guo W; Cui S; Tang X; Yan Y; Xiong F; Zhang Q; Zhao J; Mao B; Zhang H
J Sci Food Agric; 2023 Sep; 103(12):5958-5969. PubMed ID: 37099000
[TBL] [Abstract][Full Text] [Related]
25. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
Michael C; Martínez-Navarro FJ; de Oliveira S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
[TBL] [Abstract][Full Text] [Related]
27. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Sharma A; Ranvir R; Kadam S; Ingale K; Patel H; Nyska A; Jain MR
BMC Cancer; 2023 Jan; 23(1):59. PubMed ID: 36650455
[TBL] [Abstract][Full Text] [Related]
28. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.
Thompson SM; Garg I; Ehman EC; Sheedy SP; Bookwalter CA; Carter RE; Roberts LR; Venkatesh SK
Br J Radiol; 2018 Dec; 91(1092):20180345. PubMed ID: 30074820
[TBL] [Abstract][Full Text] [Related]
29. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
30. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
Casagrande V; Mauriello A; Bischetti S; Mavilio M; Federici M; Menghini R
Sci Rep; 2017 Jul; 7(1):6747. PubMed ID: 28751722
[TBL] [Abstract][Full Text] [Related]
32. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
33. Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis.
Mohammed S; Thadathil N; Ohene-Marfo P; Tran AL; Van Der Veldt M; Georgescu C; Oh S; Nicklas EH; Wang D; Haritha NH; Luo W; Janknecht R; Miller BF; Wren JD; Freeman WM; Deepa SS
Mol Cancer Res; 2023 Sep; 21(9):933-946. PubMed ID: 37204757
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma.
Thilakarathna WPDW; Rupasinghe HPV; Ridgway ND
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807605
[TBL] [Abstract][Full Text] [Related]
36. Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis.
Yang F; Zhang Y; Ren H; Wang J; Shang L; Liu Y; Zhu W; Shi X
J Exp Clin Cancer Res; 2019 Dec; 38(1):489. PubMed ID: 31831037
[TBL] [Abstract][Full Text] [Related]
37. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
38. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease.
Yu JS; Youn GS; Choi J; Kim CH; Kim BY; Yang SJ; Lee JH; Park TS; Kim BK; Kim YB; Roh SW; Min BH; Park HJ; Yoon SJ; Lee NY; Choi YR; Kim HS; Gupta H; Sung H; Han SH; Suk KT; Lee DY
Clin Transl Med; 2021 Dec; 11(12):e634. PubMed ID: 34965016
[TBL] [Abstract][Full Text] [Related]
39. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
[TBL] [Abstract][Full Text] [Related]
40. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
